SCHEMBL22147441

SCHEMBL22147441

CCOC(=O)c1cnc2cc(Br)nn2c1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.55
RAB9A P51151 6/20 0.55
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.53
TP53 P04637 3/20 0.50
RXFP1 Q9HBX9 2/20 0.50
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 8/20 0.47
GAA P10253 5/20 0.47
HPGD P15428 5/20 0.47
CYP2C19 P33261 3/20 0.47
CYP2C9 P11712 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CSNK1D P48730 2/20 0.46
MAPT P10636 2/20 0.46
GLA P06280 3/20 0.45
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL22126580 0.88 NPC1 (0.46) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL6289416 0.87 NPC1 (0.55) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL18825755 0.87 NPC1 (0.70) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL22147584 0.86 NPC1 (0.56) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL9678739 0.77 NPC1 (0.47) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL22983218 0.77 RXFP1 (0.64) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL19492504 0.77 KDM4E (0.56) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL3615280 0.76 NPC1 (0.49) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL2802194 0.75 KDM4E (0.55) NPC1RAB9AKMT2ASMN1; SMN2TP53
SCHEMBL31278243 0.74 NPC1 (0.46) NPC1RAB9AKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110612302-B Pyrazolo [1,5-a ] pyrimidine derivatives as kinase JAK inhibitors 赛隆制药股份公司 2022-06-14 CN disclosed
US-11072619-B2 Pyrazole[1,5-a] pyrimidine derivatives as kinase JAK inhibitors CELON PHARMA S.A. (PL) 2021-07-27 US disclosed
EP-3621966-B1 PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES AS KINASE JAK INHIBITORS Celon Pharma Sa (PL) 2020-11-18 EP disclosed
US-20200199128-A1 PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES AS KINASE JAK INHIBITORS CELON PHARMA S.A. (PL) 2020-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11072619-B2 Pyrazole[1,5-a] pyrimidine derivatives as kinase JAK inhibitors JAK1, JAK3, JAK2 NPC1 2526/4885RAB9A 2334/4885KMT2A 1955/4885
US-20200199128-A1 PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES AS KINASE JAK INHIBITORS JAK1, JAK3, JAK2 NPC1 2526/4885RAB9A 2334/4885KMT2A 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.